T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EXPR
1351
DELISTED
Express, Inc.
EXPR
| $7.81M | ﹤0.01% |
143,088
-12,011
| -8% | -$820K |
|
1352
TripAdvisor
TRIP
$1.29B
| $7.67M | ﹤0.01% |
165,595
+1,900
| +1% | +$92.6K |
|
1353
Cheniere Energy
LNG
$55B
| $7.66M | ﹤0.01% |
111,871
-2,306
| -2% | -$153K |
|
|
FTSV
1354
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $7.52M | ﹤0.01% |
709,796
+14,591
| +2% | +$214K |
|
|
FDC
1355
DELISTED
First Data Corporation
FDC
| $7.44M | ﹤0.01% |
274,945
+25,339
| +10% | +$659K |
|
|
WW
1356
DELISTED
WW International
WW
| $7.3M | ﹤0.01% |
382,189
-134
| -0% | -$2.65K |
|
1357
Omega Healthcare
OHI
$13.9B
| $7.26M | ﹤0.01% |
197,439
+134,402
| +213% | +$4.9M |
|
|
PGNX
1358
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $7.11M | ﹤0.01% |
1,151,552
+980,574
| +574% | +$4.73M |
|
|
STAY
1359
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $7.05M | ﹤0.01% |
417,362
-4,975
| -1% | -$87.9K |
|
1360
Zymeworks
ZYME
$1.83B
| $6.67M | ﹤0.01% |
+303,421
| New | +$5.57M |
|
|
AZUL
1361
DELISTED
Azul
AZUL
| $6.65M | ﹤0.01% |
198,888
-588,773
| -75% | -$17.1M |
|
1362
Annaly Capital Management
NLY
$17.6B
| $6.64M | ﹤0.01% |
181,801
+1,656
| +0.9% | +$63.1K |
|
|
ADVM
1363
DELISTED
Adverum Biotechnologies
ADVM
| $6.63M | ﹤0.01% |
+55,804
| New | +$4.62M |
|
|
EXTN
1364
DELISTED
Exterran Corporation
EXTN
| $6.61M | ﹤0.01% |
464,576
-377,301
| -45% | -$5.53M |
|
1365
Corvus Pharmaceuticals
CRVS
$1.27B
| $6.59M | ﹤0.01% |
1,762,248
-203,794
| -10% | -$798K |
|
|
SASR
1366
DELISTED
Sandy Spring Bancorp Inc
SASR
| $6.44M | ﹤0.01% |
184,592
-428,221
| -70% | -$14.4M |
|
1367
Wolfspeed
WOLF
$1.64B
| $6.4M | ﹤0.01% |
113,866
-266
| -0.2% | -$16.3K |
|
1368
Columbia Financial
CLBK
$1.22B
| $6.39M | ﹤0.01% |
+423,340
| New | +$6.51M |
|
1369
Puma Biotechnology
PBYI
$450M
| $6.34M | ﹤0.01% |
498,609
-287,356
| -37% | -$6.62M |
|
1370
Arch Capital
ACGL
$33.5B
| $6.24M | ﹤0.01% |
168,296
+19,053
| +13% | +$650K |
|
1371
Cibus
CBUS
$145M
| $6.2M | ﹤0.01% |
9,934
-10,740
| -52% | -$8M |
|
1372
Toll Brothers
TOL
$14B
| $6.2M | ﹤0.01% |
169,251
+17
| +0% | +$635 |
|
1373
SI-BONE Inc
SIBN
$849M
| $6.14M | ﹤0.01% |
301,793
-432,836
| -59% | -$7.43M |
|
|
ZAYO
1374
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $6.08M | ﹤0.01% |
184,864
-179,123
| -49% | -$5.72M |
|
1375
Berkshire Hathaway Class A
BRK.A
$1.09T
| $6.05M | ﹤0.01% |
19
-1
| -5% | -$311K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.